It has been demonstrated that radiolabeled PD-1 or PD-L1 antibodies can be used to non-invasively assess PD-1 or PD-L1 expression in NHPs, human tumor xenografts, and syngeneic tumor models [12–17]. This evidence concerns the gene CD274 and neoplasm.